인간성장호르몬 시장 보고서 : 용도, 유통 채널, 투여 경로, 지역별(2024-2032년)

The global human growth hormone market size reached US$ 5.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 10.9 Billion by 2032, exhibiting a growth rate (CAGR) of 7.2% during 2024-2032.

HGH is a peptide hormone that is produced by the pituitary gland to stimulate growth in children and adults. The hormone primarily regulates growth, regeneration, repair, reproduction and metabolism of the cells, thus contributing to the overall development of the body. It also regulates body fluids, fat metabolism and bone and muscle growth. The deficiency of HGH can increase the risk of diseases and fat accumulation, whereas higher levels can cause gigantism in children and acromegaly, muscle-wasting disease and short bowel syndrome in adults.

The increasing prevalence of Turner syndrome and other growth-related disorders is one of the key factors driving the growth of the market. Turner syndrome is a chromosomal disorder that primarily affects females and is characterized by complete or partial loss of X chromosomes. Growth hormones are often administered to reverse some of the symptoms of this disease, thereby increasing the demand for HGH drugs across the globe. Furthermore, increasing health consciousness among the masses and growing awareness regarding the preventive measures against endocrine disorders, are providing a boost to the market growth. Various disorders, such as Prader-Willi syndrome (PWS) and idiopathic short stature (ISS), are caused by the deficiency of growth hormones in the body that can be treated using medically synthesized HGH. Other factors, including a rising utilization of HGH as performance enhancers by bodybuilders, along with the development of recombinant human growth hormone (rHGH), are projected to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global human growth hormone market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on application, distribution channel and route of administration.

Breakup by Application:

Growth Hormone (GH) Deficiency

Adult GH Deficiency

Pediatric GH Deficiency

Turner Syndrome

Idiopathic Short Stature (ISS)

Prader-Willi Syndrome (PWS)

Small for Gestational Age

Others

Breakup by Distribution Channel:

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Others

Breakup by Route of Administration:

Intravenous

Intramuscular

Subcutaneous

Oral

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Eli Lilly and Company, EMD Serono Inc., F. Hoffmann-La Roche AG, Ferring B.V., Genentech Inc., Ipsen, Merck KGaA, Novartis AG, Novo Nordisk, Pfizer Inc., Sandoz, etc.

Key Questions Answered in This Report

• 1. How big is the global human growth hormone market?
• 2. What is the expected growth rate of the global human growth hormone market during 2024-2032?
• 3. What are the key factors driving the global human growth hormone market?
• 4. What has been the impact of COVID-19 on the global human growth hormone market?
• 5. What is the breakup of the global human growth hormone market based on the application?
• 6. What is the breakup of the global human growth hormone market based on the distribution channel?
• 7. What is the breakup of the global human growth hormone market based on the route of administration?
• 8. What are the key regions in the global human growth hormone market?
• 9. Who are the key players/companies in the global human growth hormone market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Human Growth Hormone Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Application

• 6.1 Growth Hormone (GH) Deficiency
  • 6.1.1 Market Trends
  • 6.1.2 Major Types
    • 6.1.2.1 Adult GH Deficiency
    • 6.1.2.2 Pediatric GH Deficiency
  • 6.1.3 Market Forecast
• 6.2 Turner Syndrome
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Idiopathic Short Stature (ISS)
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Prader-Willi Syndrome (PWS)
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Small for Gestational Age
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Others
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast

7 Market Breakup by Distribution Channel

• 7.1 Hospital Pharmacy
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Retail Pharmacy
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Online Pharmacy
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Route of Administration

• 8.1 Intravenous
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Intramuscular
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Subcutaneous
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Oral
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Eli Lilly and Company
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
    • 13.3.1.3 Financials
    • 13.3.1.4 SWOT Analysis
  • 13.3.2 EMD Serono Inc.
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
  • 13.3.3 F. Hoffmann-La Roche AG
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
    • 13.3.3.3 SWOT Analysis
  • 13.3.4 Ferring B.V.
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
    • 13.3.4.3 Financials
  • 13.3.5 Genentech Inc.
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
    • 13.3.5.3 SWOT Analysis
  • 13.3.6 Ipsen
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
    • 13.3.6.3 Financials
  • 13.3.7 Merck KGaA
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
    • 13.3.7.3 Financials
  • 13.3.8 Novartis AG
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
  • 13.3.9 Novo Nordisk
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio
  • 13.3.10 Pfizer Inc.
    • 13.3.10.1 Company Overview
    • 13.3.10.2 Product Portfolio
    • 13.3.10.3 Financials
    • 13.3.10.4 SWOT Analysis
  • 13.3.11 Sandoz
    • 13.3.11.1 Company Overview
    • 13.3.11.2 Product Portfolio